EML4 and non-small cell lung carcinoma: Most information currently available on the clinical efficacy and causes of relapse on crizotinib treatment are collected in the context of EML4-ALK-positive non-small-cell lung cancer, which is the most common ALK-related disease, whereas little is known about other ALK-positive malignancies.